Pennant Group Business Summary

The Pennant Group, Inc. (NASDAQ: PNTG) operates a decentralized healthcare services model, generating revenue through two primary segments: Home Health and Hospice, and Senior Living. The company’s revenue is predominantly derived from fee-for-service reimbursements from Medicare and Medicaid, alongside private-pay and value-based purchasing arrangements. As of early 2026, Pennant has significantly scaled its national footprint through the integration of major assets from Signature Healthcare at Home and divested locations from the UnitedHealth-Amedisys merger, projecting 2026 annual revenue between $1.13 billion and $1.17 billion. Within the highly fragmented post-acute care market, Pennant competes directly with industry giants such as Encompass Health (EHC), Addus HomeCare (ADUS), and Chemed Corp (CHE), distinguishing itself through an entrepreneurial, local-first leadership structure that prioritizes organic growth and margin expansion in lower-cost care settings. The leadership team is anchored by CEO and Chairman Brent Guerisoli, who has been with the organization since 2012 and succeeded founding CEO Daniel H. Walker in 2022. Guerisoli is supported by President and COO John J. Gochnour and CFO Lynette B. Walbom, both of whom possess deep operational expertise from the company’s 2019 spin-off from The Ensign Group. The board of directors features notable industry veterans, including Lead Independent Director Scott Lamb (former CFO of ICU Medical), Suzanne D. Snapper (CFO of The Ensign Group), and leadership expert Stephen M. R. Covey. Pennant maintains a strong institutional investor base, with major positions held by Van Berkom & Associates, BlackRock, and Vanguard, reflecting market confidence in its disciplined acquisition strategy and decentralized governance philosophy.